Project Grant R43AI126999

This $249,276 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a study on the real-world effectiveness of maternal respiratory syncytial virus (RSV) vaccination. RSV is a leading cause of lower respiratory tract infections in infants, contributing to 33 million episodes and 101,400 deaths annually. With no existing antiviral therapies or effective treatments,...

The U.S. Department of Agriculture (USDA) awarded a $300,000 grant under the Agriculture and Food Research Initiative (AFRI) program to Oklahoma State University (OSU) to develop a novel single-cycle vaccine against bovine respiratory syncytial virus (BRSV). The project aims to pioneer the development of two single-cycle BRSV vaccine prototypes: an 'MNull' vaccine that lacks the essential matrix protein, and a 'PRef' vaccine with a modified fusion protein. OSU will evaluate the immunogenicity...

This federal Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 Minority Health and Health Disparities Research) is intended to increase RSV vaccine uptake among Latino older adults. The $2,058,402 award to the Regents of the University of California, San Francisco will fund a 5-year research project to adapt and evaluate a community-based intervention involving community health worker counseling and text message nudges. The goal is to...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $798,173 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University to develop novel multivalent mucosal vaccines for human noroviruses. The university will generate and evaluate live-vectored vaccine candidates using the FDA-approved rotavirus (RotaTeq) and measles/mumps/rubella (MMR) vaccine platforms. The goal is to create multivalent vaccines that can induce...

This $3,056,673 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the immunological mechanisms that contribute to improved antibody response rates in people living with HIV (PLWH) when vaccinated with the Heplisav-B hepatitis B vaccine compared to the standard Engerix-B vaccine. The study has three key objectives: Define the innate immune signatures, including...

This federal Project Grant award of $883,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a thermostable measles fusion (F) glycoprotein vaccine strategy. The key objectives are to engineer a thermostable measles F protein immunogen and evaluate the protective immune responses it elicits, with the goal of creating a vaccine that is safe and effective for...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $780,834 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Michigan State University (MSU) to develop a next-generation vaccine against Bordetella pertussis, the bacterium that causes whooping cough. The key objectives of this 5-year project are to: Synthesize novel pertussis-associated glycan antigens using advanced synthetic chemistry techniques. Conjugate these synthetic glycans...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...

This $390,942 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a universal influenza vaccine using self-assembled peptide nanoparticles (SAPNs). The key goals are to: Assemble and characterize SAPNs functionalized with highly conserved influenza antigens, including the hemagglutinin stalk (HRHA) and matrix protein 2 ectodomain (4M2E), on the external surface, and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $657,506 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The grant supports research to develop a novel subunit vaccine against Bordetella pertussis, the causative agent of pertussis (whooping cough), which aims to elicit mucosal immunity and prevent nasal colonization to reduce disease transmission. The research focuses on evaluating a subunit...